Diabetes Crisis: Half of the People Living in Low-Income Countries Have No Access to Treatment
Around half of the 830 million people worldwide living with diabetes, mostly in low- and middle-income countries, lack access to proper treatment. The number of people with diabetes, as well as those without treatment, has been rising steadily for decades, especially in these regions. Access to affordable diabetes medicines is critical, yet pharmaceutical companies Eli Lilly, Novo Nordisk, and Sanofi control much of the global insulin and GLP-1 medicine market. This monopoly allows them to set high prices, limiting access in low-resource regions. Allowing competition could significantly reduce costs, similar to how generic HIV medicines became 99% cheaper over the past two decades. Expanding production would also help meet the growing global demand for insulin and diabetes care.